Breaking News

Revive Develops Lyophilized Formulation of Bucillamine

Bucillamine formulation approach offers a simple way to create a parenteral injection product with minimal formulation additives.

Revive Therapeutics Ltd., a specialty life sciences company, completed the formulation development work of the company’s next-generation lyophilized formulation of Bucillamine (New Bucillamine) conducted at the University of Waterloo. According to the company, the New Bucillamine has the potential to unlock the therapeutic utility of Bucillamine for treating public health medical emergencies, including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters